{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lechner M"],"funding":["Austrian Science Fund FWF","Cancer Research UK","NIDCR NIH HHS","Versus Arthritis","National Institute for Health Research (NIHR)","Rosetrees","Wellcome Trust"],"pagination":["117"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7785735"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["Nasopharyngeal cancer (NPC), endemic in Southeast Asia, lacks effective diagnostic and therapeutic strategies. Even in high-income countries the 5-year survival rate for stage IV NPC is less than 40%. Here we report high somatostatin receptor 2 (SSTR2) expression in multiple clinical cohorts comprising 402 primary, locally recurrent and metastatic NPCs. We show that SSTR2 expression is induced by the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) via the NF-κB pathway. Using cell-based and preclinical rodent models, we demonstrate the therapeutic potential of SSTR2 targeting using a cytotoxic drug conjugate, PEN-221, which is found to be superior to FDA-approved SSTR2-binding cytostatic agents. Furthermore, we reveal significant correlation of SSTR expression with increased rate"],"journal":["Nature communications"],"pubmed_title":["Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy."],"pmcid":["PMC7785735"],"funding_grant_id":["23900","I 3976","20522","M229-CD1","C23338/A25722","I 3976-B33","R01 DE025227","18387","25722","15965"],"pubmed_authors":["Wan S","West RB","Tsao SW","Pipinikas CP","Oppermann U","Pillay N","Philpott M","Uprimny C","Wang H","Wu F","Sutton L","Wells G","Marafioti T","Jain A","Jin H","Meyer T","Nibhani R","Royle G","Nei WL","Loke KSH","Steele CD","Fenton TR","Schartinger VH","Koller J","Xu R","Yip YL","Slim MAM","Thirlwell C","Tan B","Tay JK","Pearce W","Masterson L","He W","Chua MLK","Indrasari SR","Wollmann G","Liu J","Howard D","Morelli D","Sprung S","Forster MD","Schreiber LM","Chan YY","Han S","Cheng Z","To KF","Dudas J","Fles R","Yeong J","Le QT","Bell CG","Krapp A","Tsang CM","Gupta R","Jay A","Herdini C","Lo KW","Lund VJ","Lechner M","Busson P","Hwang PH","Chester K","Haybaeck J","Riechelmann H","Willems SM","Indrawati I","Ooft ML","Forde CT","Delecluse HJ","Delecluse S","Chung GT","Vanhaesebroeck B"],"additional_accession":[]},"is_claimable":false,"name":"Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy.","description":"Nasopharyngeal cancer (NPC), endemic in Southeast Asia, lacks effective diagnostic and therapeutic strategies. Even in high-income countries the 5-year survival rate for stage IV NPC is less than 40%. Here we report high somatostatin receptor 2 (SSTR2) expression in multiple clinical cohorts comprising 402 primary, locally recurrent and metastatic NPCs. We show that SSTR2 expression is induced by the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) via the NF-κB pathway. Using cell-based and preclinical rodent models, we demonstrate the therapeutic potential of SSTR2 targeting using a cytotoxic drug conjugate, PEN-221, which is found to be superior to FDA-approved SSTR2-binding cytostatic agents. Furthermore, we reveal significant correlation of SSTR expression with increased rate","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-04-30T16:28:59.325Z","creation":"2024-11-09T11:45:34.675Z"},"accession":"S-EPMC7785735","cross_references":{"pubmed":["33402692"],"doi":["10.1038/s41467-020-20308-8"]}}